financial results
Grail to Cut Headcount by 30 Percent in Restructuring, Reports 43 Percent Q2 Revenue Rise
Reporting its financial results as a separate company for the first time since its spinoff from Illumina, Grail said the restructuring will save it $27 million this year.
Lucid Diagnostics' Esophageal Precancer Test Sales Spike in Q2
The firm's revenues, all from the EsoGuard DNA screening test, increased to $976,000 in Q2 compared to $159,000 in the same quarter last year.
The firm's bispecific T-cell engager Blincyto and KRAS inhibitor Lumakras each provided double-digit sales growth in Q2.
Pfizer Oncology Product Revenues Jump 26 Percent in Q2
The firm reported $845 million in Q2 revenue from oncology products gained in its acquisition of Seagen last year.
Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology Candidates
The drugmaker updated investors on its three-pronged strategy to diversify its pipeline and not overly rely on its top-selling blockbuster checkpoint inhibitor.
Jul 26, 2024
Jul 18, 2024
Apr 25, 2024
Apr 25, 2024
Merck's Keytruda Sales Increase 20 Percent in Q1
Feb 7, 2024